Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
FORMULATIONS COMPRISING 6-(2-HYDROXY-2-METHYLPROPOXY)-4-(6-(6-((6-METHOXYPYRIDIN-3-YL)METHYL)-3,6-DIAZAB ICYCLO[3.1.1]HEPTAN-3-YL)PYRIDIN-3-YL)PYRAZOLO[1,5-A]PYRIDINE-3-CARBONITRILE
Document Type and Number:
WIPO Patent Application WO/2019/075114
Kind Code:
A4
Abstract:
6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.

Inventors:
REYNOLDS MARK (US)
EARY CHARLES TODD (US)
Application Number:
PCT/US2018/055285
Publication Date:
June 13, 2019
Filing Date:
October 10, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
REYNOLDS MARK (US)
EARY CHARLES TODD (US)
International Classes:
A61K47/12; A61K9/08; A61K9/16; A61K9/20; A61K31/4985; A61K47/38
Attorney, Agent or Firm:
FOLLETT, Angela D. et al. (US)
Download PDF:
Claims:
AMENDED CLAIMS

received by the International Bureau on 19 April 2019 (19.04.2019)

WE CLAIM:

1 A solid formulation comprising:

6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6- diazabicyclo[3.1.1 ]heptan-3 -yl)pyri din-3 -yl)pyrazolo [ 1 , 5 -a] pyridine-3 -carbonitrile having the Formula (I)

or a pharmaceutically acceptable salt, amorphous form, or polymorph form thereof; and

an excipient selected from the group consisting of diluents or fillers, binders, granulating agents, adhesives, polymers and copolymers, disintegrants, stabilizers, lubricants, anti-adherents, glidants, surfactants, dispersing or wetting agents, dissolution retardants or enhancers, adsorbents, buffers, chelating agents, preservatives, colors, flavors, and sweeteners, or combinations thereof.

2. The solid formulation of claim 1 , wherein the diluent or filler is selected from the group consisting of dibasic calcium phosphate, kaolin, lactose, dextrose, magnesium carbonate, sucrose, mannitol, glucose or other monosaccharaides, dextrin or other polysaccharides, microcrystalline cellulose, powdered cellulose, cellulose derivatives, precipitated calcium carbonate, calcium sulfate, sorbitol, inositol, and starch, or combinations thereof.

3 The solid formulation claim 1 or 2, wherein the diluent or filler is present in an amount of about 60 wt% to about 90 wt%.

4. The solid formulation of claim 3, wherein the diluent or filler is present in an amount of about 65 wt% to about 75 wt%.

409

5. The solid formulation of claim 3, wherein the diluent or filler is present in an amount of about 70% wt% to about 80 wt%.

6. The solid formulation of any one of claims 1-5, wherein the diluent or filler comprises microcrystalline cellulose.

7. The solid formulation of claim 6, wherein the microcrystalline cellulose is present in an amount of about 65 wt% to about 85 wt%.

8. The solid formulation of claim 6, wherein the microcrystalline cellulose is present in an amount of about 30 wt% to about 50 wt%.

9. The solid formulation of any of claims 1-8, wherein the glidant is selected from the group consisting of colloidal silica, colloidal silicon dioxide, fumed silica, silicon dioxide, cornstarch, talc, calcium silicate, magnesium silicate, tribasic calcium phosphate, and silicon hydrogel.

10. The solid formulation of any one of claims 1 to 9, wherein the dispersing agent is selected from the group consisting of a hydrophilic polymer, an electrolyte, Tween® 60 or 80, polyvinylpyrrolidone, a hydroxypropyl cellulose, a hydroxypropyl methylcellulose,

carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose,

hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropyl

methylcellulose acetate succinate (HPMC-AS), noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), vinyl pyrrolidone/vinyl acetate copolymer (S630), tyloxapol, a poloxamine, a poloxamer (poly oxypropylene-polyoxy ethylene block copolymers), a polyvinylpyrrolidone, a polyvinylpyrrolidone/vinyl acetate copolymer, polyethylene glycol (PEG), sodium carboxymethylcellulose, polysorbate-80, sodium alginate, gum tragacanth, gum acacia, guar gum, a xanthan, a sugar, polyethoxylated sorbitan

monolaurate, povidone, a carbomer, a chitosan, cellulose, and triethyl cellulose, or combinations thereof.

410

11. The solid formulation of claim 10, wherein the dispersing agent comprises hydroxypropyl methylcellulose acetate succinate (HPMC-AS).

12. The solid formulation of claim 10, wherein the dispersing agent comprises a poloxamer.

13. The solid formulation of any one of claims 1 to 12, wherein the disintegrant is selected from the group consisting of a starch, sodium carboxymethyl starch (sodium starch glycolate), pregelatinized starch (starch 1500), microcrystalline starch, water insoluble starch, sodium starch glycolate, calcium carbonate, sodium carbonate, sodium bicarbonate, cellulose and cellulose derivatives, calcium carboxymethyl cellulose, microcrystalline cellulose,

carboxymethylcellulose calcium, croscarmellose sodium, croscarmellose calcium, carmellose calcium, cellulose polacrilin potassium, magnesium aluminum silicate (Veegum), sweeteners, clays, bentonite, alginic acid, sodium alginate, alginates, gums, agar, guar, locust bean, karaya, pectin, tragacanth, citrus pulp, and crospovidone, or combinations thereof.

14. The solid formulation of claim 13, wherein the disintegrant is a cellulose derivative selected from the group consisting of calcium carboxymethyl cellulose,

microcrystalline cellulose, carboxymethylcellulose calcium, croscarmellose sodium,

croscarmellose calcium, carmellose calcium, and cellulose polacrilin potassium.

15. The solid formulation of any of claims 1 to 14 wherein the lubricant is selected from the group consisting of a stearate, stearic acid, talc, mineral oil, a silica, malt, glyceryl behenate, hydrogenated vegetable oils, polyethylene glycol, sodium benzoate, sodium acetate, sodium chloride, leucine, magnesium lauryl sulfate, and sodium lauryl sulfate, or combinations thereof.

16. The solid formulation of any one of claims 1-15 wherein the compound of Formula (I) is present in an amount from about 0.5 wt% to about 50 wt%.

17. The solid formulation of any one of claims 1-16 that is formulated as a tablet, capsule, sachet, powder, granules, coated particle, coated tablet, enterocoated tablet, enterocoated capsule, melting strip, or melting film.

18. A liquid formulation comprising:

6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6- diazabicyclo[3.1.1 ]heptan-3 -yl)pyri din-3 -yl)pyrazolo [ 1 , 5 -a] pyridine-3 -carbonitrile having the Formula (I)

or a pharmaceutically acceptable salt thereof; and

an aqueous compounding agent.

19. The liquid formulation of claim 18, wherein the aqueous compounding agent comprises a glycol, an oil, an alcohol, a flavoring agent, a preservative, a stabilizer, a coloring agent, or a combination thereof.

20. The liquid formulation of claim 18, wherein the compounding agent comprises microcrystalline cellulose, carboxymethylcellulose sodium, xanthan gum, carrageenan, or a combination thereof.

21. The liquid formulation of any one of claims 18-20, further comprising citric acid, a citrate, a lactate, a phosphate, a maleate, a tartrate, a succinate, a sulfate, or an acetate.

22. The liquid formulation of any one of claims 18-21 , wherein the compound of Formula (I) is present in a concentration of about 5 mg/mL to about 40 mg/mL.

23. The liquid formulation of claim 22, wherein the compound of Formula (I) is present in a concentration of about 10 mg/mL to about 30 mg/mL.

24. The liquid formulation of any one of claims 18-23, further comprising a sweetener.

25. The liquid formulation of claim 24, wherein the sweetener comprises sucrose, glycerin, sorbitol, or sodium saccharin, xanthan gum, or a combination thereof.

26. The liquid formulation of any one of claims 18-25, wherein the liquid formulation is prepared from, at least in part, a crystalline form of the compound of Formula (I) or a pharmaceutically acceptable salt thereof.

413